Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT)

被引：0
|
作者：
Jason T. Hurwitz
Shannon Vaffis
Amy J. Grizzle
Søren Nielsen
Andrew Dodson
Suzanne Parry
机构：
[1] University of Arizona,Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy
[2] Aalborg University Hospital,NordiQC, Institute of Pathology
[3] UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ Hybridisation,undefined
来源：
Oncology and Therapy | 2022年 / 10卷
关键词：
Advanced NSCLC; Cost-effectiveness; Diagnostic; Germany; PD-L1; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：391 / 409
页数：18
相关论文
共 50 条
  • [41] TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
    Cao, Xiaobo
    Zhao, Yang
    Wang, Jing
    Dai, Bingbing
    Gentile, Emanuela
    Lin, Jing
    Pu, Xingxiang
    Ji, Lin
    Wu, Shuhong
    Meraz, Ismail
    Majidi, Mourad
    Roth, Jack A.
    ONCOTARGET, 2017, 8 (64) : 107621 - 107629
  • [42] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
    Naito, Tomoyuki
    Shiraishi, Hideaki
    Fujiwara, Yutaka
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105
  • [43] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404
  • [44] Current PD-L1 immunohistochemistry for non-small cell lung cancer
    Scheel, Andreas H.
    Schaefer, Stephan C.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1217 - 1219
  • [45] PD-L1 Expression in Patients with Non-small Cell Lung Cancer
    Masago, Katsuhiro
    Fujita, Shiro
    Hata, Akito
    Okuda, Chiyuki
    Kaji, Reiko
    Katakami, Nobuyuki
    Hirata, Yukio
    ANTICANCER RESEARCH, 2017, 37 (05) : 2269 - 2274
  • [46] PD-L1 heterogeneity in patients with non-small cell lung cancer
    Wei, Zhigang
    Fan, Linlin
    Yang, Xia
    Li, Jie
    Zhan, Xuemei
    Ye, Xin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E268 - E274
  • [47] PD-L1 immunohistochemistry in patients with non-small cell lung cancer
    Jotatsu, Takanobu
    Oda, Keishi
    Yatera, Kazuhiro
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2127 - S2129
  • [48] IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer
    Mino-Kenudson, M.
    Redman, M.
    Hedger, J.
    Daigneault, J.
    Botling, J.
    Brambilla, E.
    Chen, G.
    Chou, T.
    Cooper, W.
    Hirsch, F. R.
    Jain, D.
    Kerr, K.
    Longshore, J.
    Lopez-Rios, F.
    Motoi, N.
    Pelosi, G.
    Tsao, M.
    Yatabe, Y.
    Beasley, M. B.
    Borczuk, A.
    Bubendorf, L.
    Chung, J.
    Dacic, S.
    Hwang, D.
    Minami, Y.
    Moreira, A.
    Nicholson, A.
    Papotti, M.
    Poleri, C.
    Rekhtman, N.
    Roden, A. C.
    Russell, P.
    Sholl, L.
    Thunnissen, E.
    Travis, W.
    Yoshida, A.
    Wynes, M.
    Wistuba, I.
    Lantuejoul, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S778 - S779
  • [49] BIOMARKER AND PD-L1 TESTING FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER IN COMMUNITY PRACTICE
    Rivera, M. Patricia
    Perera, Pasangi
    Throneburg, Allison
    Lane, Lindsay
    Charlot, Marjory
    Samulski, Teresa
    Durham, Danielle
    Henderson, Louise
    CHEST, 2020, 158 (04) : 1459A - 1459A
  • [50] Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Vecchiarelli, S.
    D'Incecco, A.
    Minuti, G.
    Gallo, M.
    De Luca, A.
    Landi, L.
    Bennati, C.
    Spreafico, M.
    D'Arcangelo, M.
    Attilia, L.
    Mazza, V.
    Normanno, N.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2389 - S2389
12345